Baird analyst Michael Ulz lowered the price target on BioMarin ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $102 at Credit Suisse, After FDA CRLAugust 19, 2020 11:28 AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $113 at SVB Leerink, After FDA CRLAugust 19, 2020 11:26 AM RBC Capital Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Sector Perform, After FDA CRLAugust 19, 2020 11:12 AM BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $188 at Goldman Sachs, After FDA CRLAugust 19, 2020 11:07 AM Evercore ISI Downgrades BioMarin Pharmaceutical Inc. (BMRN) to In LineAugust 19, 2020 10:09 AM Increasing unusual put option volume: BMRN HEXOAugust 19, 2020 9:40 AM Pre-Open Stock Movers 08/19: (MNTA) (HUD) (IMVT) Higher; (BMRN) (GLPG) (VIPS) Lower (more...)August 19, 2020 9:26 AM Stifel Downgrades BioMarin Pharmaceutical Inc. (BMRN) to HoldAugust 19, 2020 9:26 AM Sangamo Therapeutics (SGMO) Gains on BioMarin (BMRN) CRLAugust 19, 2020 9:13 AM BioMarin Pharma (BMRN) Receives CRL from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia AAugust 19, 2020 8:02 AM BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia AAugust 19, 2020 8:00 AM